Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Super Generics – The Next Step For Generic Players As Commoditized Drugs Yield Less Margins – DIA India Conference

This article was originally published in PharmAsia News

Executive Summary

It takes tremendous efforts but generic companies eye complex drugs for lasting gains, said DIA India speakers.

You may also be interested in...

Dr. Reddy's Labs Saved From Poor India Showing By North America Market Growth, Biosimilars

MUMBAI - Dr. Reddy's Laboratories Ltd. faced an unexpected slowdown in its home market as sales growth in India slipped to just 6% during the first quarter - remarkably lower than the industry average of 14% to 15% - but a 69% rise in sales of its biosimilars products like monoclonal antibody Reditux (rituximab) powered revenues to a respectable $66 million, against $62 million achieved during the same period last year

Actavis Eyes Acquisitions In The Middle East And Niche Products In The U.S.

Possibly acquiring development expertise in biosimilars from the Swiss firm BioPartners is one of several strategic moves that newly appointed chief executive Claudio Albrecht is now making at the generics company Actavis

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts